About Us 2021-12-22T21:40:08+00:00

About CNS

About CNS

Founded in 2000, CNS has grown to become one of the largest clinical research providers in the country, and the largest in Southern California. CNS operates three outpatient clinics located in Southern California (Garden Grove, Long Beach and Torrance).

What We Do

CNS, in partnerships with major pharmaceutical sponsors, conducts clinical trials for new medications and treatments in various therapeutic areas including neurology, psychiatry and general health conditions.


Mission Statement

The mission of CNS is to advance medical knowledge through seamless execution of complex clinical trials utilizing our extensive experience, knowledge and capabilities.



David P. Walling, Ph.D., Chief Executive Officer

Dr. Walling received his doctorate in Counseling Psychology from the University of Southern California. He attended California State University, Long Beach, earning a master’s degree in Counseling as well as a bachelor’s degree in Psychology. Prior to CNS, Dr. Walling was Vice President of Clinical Services at Psychiatric Management Resources & Stadt Solutions Pharmacy Corporation. He has also served as an Assistant Professor and Research Scientist in Psychiatry and Behavioral Sciences at the University of Texas Medical Branch at Galveston. Dr. Walling has clinical experience as a licensed psychologist and marriage, family, and child counselor. He currently holds the position of Chief Executive Officer as well as serving as Principal Investigator on multiple clinical research studies conducted at CNS.


Armen Goenjian, M.D., D.F.A.P.A., F.A.C.G.S., Chief Medical Officer

Dr. Goenjian received his Bachelors of Science degree at the American University of Beirut and Doctorate in Medicine at the University of Tennessee. He is a Diplomate of the American Board of Psychiatry and Neurology in Psychiatry and Diplomate of the American Board of Geriatrics. He is affiliated with Memorial Counseling Associates (MCA) in Long Beach, and is Research Professor of Psychiatry at the David Geffen School of Medicine at UCLA. He is the Senior Medical Director at MCA, and Chief Medical Officer and Principal Investigator at CNS. Additionally, he has his own private practice in Long Beach. Not only does Dr. Goenjian dedicate his time to research, but he believes in giving back to the community by doing humanitarian work. Dr. Goenjian has consulted and provided training to mental health workers after multiple natural disasters abroad.


Dalia Botros, MBBS, Chief Operating Officer

Ms. Botros attended the Alexandria University School of Medicine in Egypt, where she was a General Physician as well as an Obstetrician/Gynecologist. She is currently the Site Director of CNS’s Early Phase Research site in Long Beach, CA. Prior to CNS, she was a Clinical Research Coordinator for multiple Phase I-IV clinical trials. She has also been an Assistant Research Director where she supervised Research Coordinators, ensuring studies were conducted in compliance with FDA regulations and ICH guidelines. Ms. Botros has published numerous clinical studies and poster presentations and has been a guest speaker for a variety of pharmaceutical companies.


Larry Ereshefsky, Pharm.D., Chief Science Officer

Dr. Ereshefsky is the Chief Scientific Officer at CNS. Dr. Ereshefsky is an internationally recognized thought leader in clinical translational CNS research with a proven track record in designing and performing Phase I/IIa and clinical pharmacology studies. He pioneered neurocircuitry/biomarker-based (RDoC) studies incorporating qEEG, ERP, PSG, fMRI, MRS, PET, pain models, and CSF collection. He has more than 45 years of drug discovery and development experience including Program Director Psychopharmacology/ Professor, University of Texas Health San Antonio, CSO for California Clinical Trials, and Global CNS Lead, Early Phase PAREXEL. During his career, he served as a PI on more than 100 studies and several hundred more as a sub-I. Dr. Ereshefsky has been a designer and investigator on over 100 Asian Bridging trials, and he co-created the ex-Japan, US-based strategy.

Over the last four decades, Dr. Ereshefsky has contributed 100+ Scholarly Presentations/Keynote addresses and published 200+ Research/ Clinical practice Articles/ Abstracts/ Posters, of which 150 are Peer Reviewed. Since the early 1970s, he has served on numerous professional societies as an officer or board member. He served two terms on the FDA Psychopharmacological Drugs Advisory Committee, several terms on the USP-Panel for Psychiatry, and Co-chairs two ISCTM Working Groups on Behavioral and Psychological Symptoms of Dementia, with FDA, EMA, AAIC, NIMH, and IPA participation, resulting in Diagnostic Criteria and publications delineating a road map for drug development.

Dr. Ereshefsky received his Pharm.D. from the University of Southern California. His post Post- Graduate Residency in Psychiatric Pharmacy/ Psychopharmacology was completed at LA County Medical Center.


Shawna Cote, MS, CCRA, CCRC

Fueled by an extensive background in clinical research, Ms. Cote has led the administration of Pacific Research Partners since its inception in July 2010. She brings with her over 10 years of experience as a Contract Research Monitor and a 14-year history of site management. Ms. Cote earned a Masters of Science in Clinical Trial Administration from Walden University as well as CCRC and CCRA certifications from the Association of Clinical Research Professionals.


Steven Trembley

Steven Trembley joined CNS Network in 2018 and serves as the Company’s Chief Financial Officer. Mr. Trembley earned his Bachelor of Arts from Claremont McKenna College. Since College, he spent the next 20 years working in investment banking and private equity. He also worked very closely for a number of years with several family-owned businesses in senior finance roles and as a Board of Director member.


South Bay  •  Orange County  •  Long Beach  

Hi all, Dr. [Nirav] Patel, Anne Cabral, and the team to acknowledge the outstanding job we all did on the study! As an add-on site we enrolled 15 patients in 8 months. According to some of his internal metrics, we were performing at 300+% compared to other sites. That is amazing! Just wanted to share with all of you the great work the team has done. GREAT JOB, EVERYONE!

Study Sponsor